Soligenix, Inc. (SNGX) announced a publication describing the preclinical efficacy of a single-vial, bivalent vaccine providing protection against both Sudan ebolavirus and Marburg marburgvirus infections. The company said the published paper describes the potency of the bivalent formulation against both viruses, showing 100% protection in the most rigorous non-human primate challenge models.
Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need.
Shares of Soligenix are up 14% in pre-market trade on Tuesday.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.